AbbVie Inc. (ABBV) Stock Analysis
Latest ClaritX AI analysis ·
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL)
| Metric | Value |
|---|---|
| Price | $262.82 |
| Market cap | $464.3B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| ClaritX AI score | 90/100 |
| Price/Book | -78.42 |
| Dividend yield | 2.60% |
| Beta | 0.28 |
AI verdict
Synthesizing the fundamental and technical landscape as of October 05, 2026, AbbVie Inc. (ABBV) unequivocally solidifies its status as a premier defensive cornerstone equity. Currently trading at $262.82, the asset sits exactly 2.44% below its absolute 52-week high of $269.39. Coupled with an exceptionally low beta of 0.281, this tight proximity to peak pricing highlights methodical, unyielding institutional accumulation rather than volatile retail speculation. A stock trading near all-time highs with such defensive characteristics serves as an optimal risk-adjusted vehicle. Crucially, the short-term technicals have executed a flawless divergence, with the 14-day RSI cooling down to a highly sustainable 53.13 despite recent price appreciation. This successfully neutralizes immediate downside risk while maintaining pristine alignment above all primary moving averages. Fundamentally, AbbVie remains an absolute cash-generating fortress. The enterprise produces an elite $11.11 in free cash flow per share, easily covering its $6.83 dividend for a highly secure true cash payout ratio of 61.47%, entirely invalidating any GAAP accounting distortions. Wall Street's $315.00 consensus price target implies a massive 19.8% upside runway, fundamentally validated by recent pipeline victories including the FDA approval of a new once-daily Parkinson's pill. AbbVie perfectly blends inflation-resistant income with defensive capital appreciation. Rating 90/100
What this score has been worth
ClaritX scores ABBV 90 out of 100 (snapshot 2026-10-05).
Every ClaritX analysis is scored first and judged only on what the stock did afterwards. Across the 56 analyses that scored in the 90-100 band, the average forward return was -0.8% with a 48% win rate, -6.2pp against the S&P 500. That is a measured tendency across many names, not a forecast for ABBV — roughly 52% of stocks in this band still lost money.
The full band-by-band table, including the bands that lost, is on the AI Rank Report; the live strategy arms behind it are on the AI Track Record, losses published.